FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2769127014> ?p ?o ?g. }

• W2769127014 endingPage "3370" @default.
• W2769127014 startingPage "3361" @default.
• W2769127014 abstract "Eosinophilic and non-eosinophilic COPD patients with chronic respiratory failure: neutrophil-to-lymphocyte ratio as an exacerbation marker Eylem Acartürk Tunçay, Zuhal Karakurt, Emine Aksoy, Cuneyt Saltürk, Sinem Gungor, Nezihe Ciftaslan, İlim Irmak, Dilek Yavuz, Birsen Ocakli, Nalan Adıgüzel Respiratory Intensive Care Unit, Sureyyapaşa Chest Diseases and Thoracic Surgery Education and Research Hospital, University of Health Sciences, Istanbul, Turkey Aim: Increased dyspnea, sputum volume, and purulence are subjective symptoms in COPD patients. To diagnose COPD exacerbations with chronic respiratory failure (CRF) and to assess the requirement for antibiotic treatment, physicians require more objective criteria. We aimed to investigate whether neutrophil-to-lymphocyte ratio (NLR) can be used as an infectious exacerbation marker in COPD patients with CRF.Patients and methods: This retrospective cross-sectional study was performed in the intensive care outpatient clinic of a tertiary training hospital between 2014 and 2015. Patients admitted with CRF due to COPD and who had complete blood count (CBC) results were enrolled. CBC results and C-reactive protein (CRP) levels were obtained from the hospital online database. The “modified exacerbation model (MEM)” was defined as follows: exacerbation A, leukocytes ≥12,000/mm3, CRP >10 mg/dL; exacerbation B, leukocytes ≥10,000/mm3, CRP >10 mg/dL; exacerbation C, leukocytes ≥10,000/mm3, CRP >8 mg/dL; exacerbation D, leukocytes ≥10,000/mm3, CRP >5 mg/dL. The cutoff value of NLR was defined for each model. Patients were split into two groups based on the NLR cutoff value according to the “NLR exacerbation model” and further subgrouped according to peripheral eosinophil percentage (eosinophils ≥2% and <2%) and compared with the MEM.Results: A total of 1,066 COPD patients (430 females, 40.3%), with a mean age of 66±13 years, were included. A NLR cutoff value of 3.54 (NLR ≥3.54, n=366, 34%) showed the highest sensitivity and specificity for model A (78%, 69%), model B (63%, 71%), model C (61%, 72%), and model D (58%, 72%). Peripheral eosinophilia (PE ≥2%) was present in 48 patients (4.5%). The ratio of patients with PE <2% in the NLR ≥3.54 group was significantly higher in the MEM (P<0.001).Conclusion: The NLR presents an attractive option as an exacerbation marker in COPD patients with CRF due to its simplicity and cost-effectiveness. In COPD patients with CRF, where the NLR is ≥3.54, PE levels are <2%, and subjective symptoms are present, antibiotic treatment should be considered. Keywords: COPD, exacerbation, chronic respiratory failure, neutrophil-to-lymphocyte ratio, peripheral eosinophilia" @default.
• W2769127014 created "2017-12-04" @default.
• W2769127014 creator A5000552937 @default.
• W2769127014 creator A5006678132 @default.
• W2769127014 creator A5008946656 @default.
• W2769127014 creator A5012889488 @default.
• W2769127014 creator A5041481434 @default.
• W2769127014 creator A5043349374 @default.
• W2769127014 creator A5047434987 @default.
• W2769127014 creator A5051558247 @default.
• W2769127014 creator A5074935800 @default.
• W2769127014 creator A5081163272 @default.
• W2769127014 date "2017-11-01" @default.
• W2769127014 modified "2023-10-18" @default.
• W2769127014 title "Eosinophilic and non-eosinophilic COPD patients with chronic respiratory failure: neutrophil-to-lymphocyte ratio as an exacerbation marker" @default.
• W2769127014 cites W1563708275 @default.
• W2769127014 cites W1760281680 @default.
• W2769127014 cites W1789525100 @default.
• W2769127014 cites W1972175300 @default.
• W2769127014 cites W1973166067 @default.
• W2769127014 cites W1982305754 @default.
• W2769127014 cites W2012519534 @default.
• W2769127014 cites W2018446948 @default.
• W2769127014 cites W2033380992 @default.
• W2769127014 cites W2042814134 @default.
• W2769127014 cites W2043714428 @default.
• W2769127014 cites W2053864720 @default.
• W2769127014 cites W2065130324 @default.
• W2769127014 cites W2078625967 @default.
• W2769127014 cites W2093577653 @default.
• W2769127014 cites W2104168490 @default.
• W2769127014 cites W2104349427 @default.
• W2769127014 cites W2107563747 @default.
• W2769127014 cites W2121676520 @default.
• W2769127014 cites W2131492263 @default.
• W2769127014 cites W2134492231 @default.
• W2769127014 cites W2144400988 @default.
• W2769127014 cites W2146877487 @default.
• W2769127014 cites W2150604729 @default.
• W2769127014 cites W2163427266 @default.
• W2769127014 cites W2168796298 @default.
• W2769127014 cites W2202941621 @default.
• W2769127014 cites W2269941404 @default.
• W2769127014 cites W2302490118 @default.
• W2769127014 cites W2305436842 @default.
• W2769127014 cites W2522425666 @default.
• W2769127014 cites W2529506617 @default.
• W2769127014 cites W2569499583 @default.
• W2769127014 cites W2587991106 @default.
• W2769127014 cites W2604596332 @default.
• W2769127014 cites W4249938147 @default.
• W2769127014 doi "https://doi.org/10.2147/copd.s147261" @default.
• W2769127014 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5703161" @default.
• W2769127014 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29200843" @default.
• W2769127014 hasPublicationYear "2017" @default.
• W2769127014 type Work @default.
• W2769127014 sameAs 2769127014 @default.
• W2769127014 citedByCount "20" @default.
• W2769127014 countsByYear W27691270142018 @default.
• W2769127014 countsByYear W27691270142019 @default.
• W2769127014 countsByYear W27691270142020 @default.
• W2769127014 countsByYear W27691270142021 @default.
• W2769127014 countsByYear W27691270142022 @default.
• W2769127014 countsByYear W27691270142023 @default.
• W2769127014 crossrefType "journal-article" @default.
• W2769127014 hasAuthorship W2769127014A5000552937 @default.
• W2769127014 hasAuthorship W2769127014A5006678132 @default.
• W2769127014 hasAuthorship W2769127014A5008946656 @default.
• W2769127014 hasAuthorship W2769127014A5012889488 @default.
• W2769127014 hasAuthorship W2769127014A5041481434 @default.
• W2769127014 hasAuthorship W2769127014A5043349374 @default.
• W2769127014 hasAuthorship W2769127014A5047434987 @default.
• W2769127014 hasAuthorship W2769127014A5051558247 @default.
• W2769127014 hasAuthorship W2769127014A5074935800 @default.
• W2769127014 hasAuthorship W2769127014A5081163272 @default.
• W2769127014 hasBestOaLocation W27691270141 @default.
• W2769127014 hasConcept C126322002 @default.
• W2769127014 hasConcept C142724271 @default.
• W2769127014 hasConcept C203014093 @default.
• W2769127014 hasConcept C2776301714 @default.
• W2769127014 hasConcept C2776780178 @default.
• W2769127014 hasConcept C2776888751 @default.
• W2769127014 hasConcept C2777014857 @default.
• W2769127014 hasConcept C2777761686 @default.
• W2769127014 hasConcept C2778963024 @default.
• W2769127014 hasConcept C2779758542 @default.
• W2769127014 hasConcept C2781069245 @default.
• W2769127014 hasConcept C3020110884 @default.
• W2769127014 hasConcept C71924100 @default.
• W2769127014 hasConcept C90924648 @default.
• W2769127014 hasConceptScore W2769127014C126322002 @default.
• W2769127014 hasConceptScore W2769127014C142724271 @default.
• W2769127014 hasConceptScore W2769127014C203014093 @default.
• W2769127014 hasConceptScore W2769127014C2776301714 @default.
• W2769127014 hasConceptScore W2769127014C2776780178 @default.
• W2769127014 hasConceptScore W2769127014C2776888751 @default.
• W2769127014 hasConceptScore W2769127014C2777014857 @default.
• W2769127014 hasConceptScore W2769127014C2777761686 @default.

• next